Clinical trials with iotrolan in myelographic and computed tomography applications in the United States.
Iotrolan, a new nonionic contrast agent, was studied in the United States using 190 mg I/ml, 240 mg I/ml, and 300 mg I/ml concentrations. Procedures performed were lumbar, thoracic, cervical, and total columnar myelography and computed tomography applications. Two multicenter double-blind studies (iotrolan versus metrizamide in 190 mg I/ml and 240 mg I/ml concentrations) and five open-label studies were conducted in a total of 863 patients (569 iotrolan, 294 metrizamide). Iotrolan and metrizamide both demonstrated diagnostic efficacy. Iotrolan demonstrated better patient tolerance in comparison with metrizamide.
Goldstein
H A
HA
Pfennig
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage*; D006801:Humans; D007463:Iodobenzoates; D008793:Metrizamide; D008875:Middle Aged; D009192:Myelography; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids; D014481:United States
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C033300:iotrolan; D008793:Metrizamide